CY1121602T1 - Συνθεση της κοπανλισιμπης και του διυδροχλωρικου αλατος της - Google Patents

Συνθεση της κοπανλισιμπης και του διυδροχλωρικου αλατος της

Info

Publication number
CY1121602T1
CY1121602T1 CY20191100444T CY191100444T CY1121602T1 CY 1121602 T1 CY1121602 T1 CY 1121602T1 CY 20191100444 T CY20191100444 T CY 20191100444T CY 191100444 T CY191100444 T CY 191100444T CY 1121602 T1 CY1121602 T1 CY 1121602T1
Authority
CY
Cyprus
Prior art keywords
copanalisib
dihydrochloride
kopanlisimpi
dihydrochlorate
composition
Prior art date
Application number
CY20191100444T
Other languages
English (en)
Inventor
Jan Georg PETERS
Philipp Rubenbauer
Daniel Götz
Danja Grossbach
Franz-Josef Mais
Heiko Schirmer
Juergen Stiehl
Kai Lovis
Andreas Lender
Martin Seyfried
Theodor Zweifel
Maurus Marty
Günter Weingärtner
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of CY1121602T1 publication Critical patent/CY1121602T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Η παρούσα εφεύρεση σχετίζεται με μία νέα μέθοδο παρασκευής της κοπανλισίμπης, της διυδροχλωρικής κοπανλισίμπης ή των ένυδρων μορφών της διυδροχλωρικής κοπανλισίμπης, με νέες ενδιάμεσες χημικές ενώσεις και με τη χρήση των εν λόγω νέων ενδιάμεσων χημικών ενώσεων για την παρασκευή της εν λόγω κοπανλισίμπης, της διυδροχλωρικής κοπανλισίμπης ή των ένυδρων μορφών της διυδροχλωρικής κοπανλισίμπης. Η παρούσα εφεύρεση σχετίζεται, επίσης, με ένυδρες μορφές της διυδροχλωρικής κοπανλισίμπης, ως χημικές ενώσεις.
CY20191100444T 2014-11-07 2019-04-23 Συνθεση της κοπανλισιμπης και του διυδροχλωρικου αλατος της CY1121602T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14192203.9A EP3018127A1 (en) 2014-11-07 2014-11-07 Synthesis of copanlisib and its dihydrochloride salt
PCT/EP2015/075789 WO2016071435A2 (en) 2014-11-07 2015-11-05 Synthesis of copanlisib and its dihydrochloride salt

Publications (1)

Publication Number Publication Date
CY1121602T1 true CY1121602T1 (el) 2020-05-29

Family

ID=51866061

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100444T CY1121602T1 (el) 2014-11-07 2019-04-23 Συνθεση της κοπανλισιμπης και του διυδροχλωρικου αλατος της

Country Status (47)

Country Link
US (1) US10494372B2 (el)
EP (2) EP3018127A1 (el)
JP (1) JP6691115B2 (el)
KR (1) KR102566834B1 (el)
CN (1) CN107278204B (el)
AR (1) AR102570A1 (el)
AU (1) AU2015341788B2 (el)
BR (1) BR112017009470B1 (el)
CA (1) CA2966800C (el)
CL (1) CL2017001131A1 (el)
CO (1) CO2017004532A2 (el)
CR (1) CR20170184A (el)
CU (1) CU24489B1 (el)
CY (1) CY1121602T1 (el)
DK (1) DK3215493T3 (el)
DO (1) DOP2017000112A (el)
EA (1) EA035558B1 (el)
EC (1) ECSP17027755A (el)
ES (1) ES2721778T3 (el)
HK (1) HK1245774A1 (el)
HR (1) HRP20190720T1 (el)
HU (1) HUE042866T2 (el)
IL (1) IL251874A0 (el)
JO (1) JO3644B1 (el)
LT (1) LT3215493T (el)
MA (1) MA40895B1 (el)
ME (1) ME03358B (el)
MX (1) MX366904B (el)
MY (1) MY189852A (el)
NI (1) NI201700054A (el)
NZ (1) NZ731287A (el)
PE (1) PE20170897A1 (el)
PH (1) PH12017500833A1 (el)
PL (1) PL3215493T3 (el)
PT (1) PT3215493T (el)
RS (1) RS58579B1 (el)
SA (1) SA517381462B1 (el)
SG (1) SG11201703702RA (el)
SI (1) SI3215493T1 (el)
SV (1) SV2017005433A (el)
TN (1) TN2017000179A1 (el)
TR (1) TR201905217T4 (el)
TW (1) TWI697495B (el)
UA (1) UA122398C2 (el)
UY (1) UY36392A (el)
WO (1) WO2016071435A2 (el)
ZA (1) ZA201703867B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CA2908776C (en) 2013-04-08 2021-08-10 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
EP3268490B1 (en) 2015-03-09 2020-07-08 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
CN108884098B (zh) 2016-03-08 2021-09-14 拜耳制药股份公司 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
CA3037626A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
CU24607B1 (es) 2017-09-08 2022-06-06 Bayer Consumer Care Ag Sólido estable, liofilizado, que contiene copanlisib, útil para dilución y aplicaciones terapéuticas
WO2023139125A1 (en) 2022-01-18 2023-07-27 Synthon B.V. Improved process for preparation of copanlisib
WO2023218032A1 (en) 2022-05-13 2023-11-16 Synthon B.V. Solid forms of copanlisib salts

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003580A (en) 1910-08-10 1911-09-19 Remington Typewriter Co Type-writing machine.
US6221877B1 (en) * 2000-04-12 2001-04-24 Regents Of The University Of California Substituted 4-phthalimidocarboxanilides as inhibitors of purine salvage phosphoribosyltransferases
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
TW565582B (en) * 2001-04-13 2003-12-11 Kaneka Corp Diamine, acid dianhydride, and reactive group containing polyimide composition prepared therefrom and preparing them
EP1417204B1 (en) * 2001-08-15 2006-01-18 E. I. du Pont de Nemours and Company Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests
ES2312843T3 (es) 2002-09-30 2009-03-01 Bayer Healthcare Ag Derivados de azolpirimidina condensados.
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
CA2713388C (en) * 2008-01-14 2016-03-29 William Scott Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CA2908776C (en) 2013-04-08 2021-08-10 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
EP3077002B1 (en) 2013-12-03 2020-04-22 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
AU2016231260A1 (en) 2015-03-09 2017-09-21 Bayer Healthcare Pharmaceuticals Inc. Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP3268490B1 (en) 2015-03-09 2020-07-08 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
AU2017214230A1 (en) 2016-02-01 2018-08-09 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
WO2017134030A1 (en) 2016-02-01 2017-08-10 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
CN108884098B (zh) 2016-03-08 2021-09-14 拜耳制药股份公司 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
CA3037626A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors

Also Published As

Publication number Publication date
HUE042866T2 (hu) 2019-07-29
SV2017005433A (es) 2018-04-30
JP2017534631A (ja) 2017-11-24
MX2017005893A (es) 2017-06-30
PL3215493T3 (pl) 2019-07-31
CR20170184A (es) 2017-06-20
ES2721778T3 (es) 2019-08-05
AR102570A1 (es) 2017-03-08
KR20170082563A (ko) 2017-07-14
EP3215493A2 (en) 2017-09-13
PH12017500833A1 (en) 2017-10-18
DK3215493T3 (da) 2019-05-06
LT3215493T (lt) 2019-04-25
DOP2017000112A (es) 2017-06-15
KR102566834B1 (ko) 2023-08-16
PE20170897A1 (es) 2017-07-12
AU2015341788B2 (en) 2020-01-16
MA40895A (fr) 2017-09-13
BR112017009470A2 (pt) 2018-01-02
SI3215493T1 (sl) 2019-05-31
CO2017004532A2 (es) 2017-07-19
NZ731287A (en) 2023-01-27
ECSP17027755A (es) 2017-06-30
SA517381462B1 (ar) 2021-01-25
CA2966800A1 (en) 2016-05-12
UA122398C2 (uk) 2020-11-10
IL251874A0 (en) 2017-06-29
BR112017009470B1 (pt) 2022-11-01
NI201700054A (es) 2017-07-17
WO2016071435A3 (en) 2016-06-30
ME03358B (me) 2019-10-20
EA035558B1 (ru) 2020-07-07
EA201790983A1 (ru) 2017-10-31
US20180282337A1 (en) 2018-10-04
MY189852A (en) 2022-03-14
CA2966800C (en) 2023-02-21
AU2015341788A1 (en) 2017-05-18
TN2017000179A1 (en) 2018-10-19
CU24489B1 (es) 2020-12-17
HK1245774A1 (zh) 2018-08-31
CL2017001131A1 (es) 2018-01-19
RS58579B1 (sr) 2019-05-31
SG11201703702RA (en) 2017-06-29
MA40895B1 (fr) 2019-07-31
US10494372B2 (en) 2019-12-03
JO3644B1 (ar) 2020-08-27
JP6691115B2 (ja) 2020-04-28
CN107278204B (zh) 2019-12-17
CU20170061A7 (es) 2017-10-05
TWI697495B (zh) 2020-07-01
HRP20190720T1 (hr) 2019-06-14
MX366904B (es) 2019-07-30
TR201905217T4 (tr) 2019-05-21
TW201625634A (zh) 2016-07-16
ZA201703867B (en) 2019-07-31
WO2016071435A2 (en) 2016-05-12
PT3215493T (pt) 2019-05-21
EP3018127A1 (en) 2016-05-11
EP3215493B1 (en) 2019-01-23
CN107278204A (zh) 2017-10-20
UY36392A (es) 2016-06-30

Similar Documents

Publication Publication Date Title
CY1121602T1 (el) Συνθεση της κοπανλισιμπης και του διυδροχλωρικου αλατος της
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
EA202092435A2 (ru) Моноклональные антитела против bcma
BR112018069612A2 (pt) compostos de pirroltriazina como inibidores de tam
EA201891211A1 (ru) Ингибиторы cxcr2
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
EA201692219A1 (ru) Способы получения противовирусных соединений
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
TR201909606T4 (tr) Pi̇razollari hazirlamak i̇çi̇n i̇şlem
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида
TR201910057T4 (tr) Kauçuk bi̇leşi̇mleri̇
CY1125143T1 (el) Νεα αλατα νιλοτινιμπης και πολυμορφα αυτων
EA201891586A1 (ru) Антипролиферативные соединения и их фармацевтические композиции и применения
CR20170005A (es) Derivados de insoindolina
CY1120763T1 (el) Νεες ενωσεις σουλφονυλαμινοβενζαμιδιου
CL2017000151A1 (es) Derivados de piridona
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
CL2018002756A1 (es) Un proceso mejorado para la preparación de tartrato de butorfanol.
TR201901516T4 (tr) Nöroprotektif ajanlar ve bunların kullanımları.
BR112017019176A2 (pt) processos para a preparação de fluorocetolídeos
BR112016027455A2 (pt) moduladores ppar
EA201791645A1 (ru) Новые соли и полиморфы scy-078